133 related articles for article (PubMed ID: 1673407)
1. Redistribution of tricyclic antidepressants in rats using a drug-specific monoclonal antibody: dose-response relationship.
Pentel PR; Keyler DE; Brunn GJ; Milavetz JM; Gilbertson DG; Matta SG; Pond SM
Drug Metab Dispos; 1991; 19(1):24-8. PubMed ID: 1673407
[TBL] [Abstract][Full Text] [Related]
2. Influence of various combinations of specific antibody dose and affinity on tissue imipramine redistribution.
Ragusi C; Boschi G; Risède P; Rips R; Harrison K; Scherrmann JM
Br J Pharmacol; 1998 Sep; 125(1):35-40. PubMed ID: 9776341
[TBL] [Abstract][Full Text] [Related]
3. Hepatic metabolism of imipramine after prolonged administration of the drug to rats. An in vivo study.
Melzacka M; Danek L; Adamus A
Pol J Pharmacol Pharm; 1987; 39(4):379-86. PubMed ID: 3449809
[TBL] [Abstract][Full Text] [Related]
4. Reversal of desipramine toxicity in rats using drug-specific antibody Fab' fragment: effects on hypotension and interaction with sodium bicarbonate.
Brunn GJ; Keyler DE; Pond SM; Pentel PR
J Pharmacol Exp Ther; 1992 Mar; 260(3):1392-9. PubMed ID: 1312169
[TBL] [Abstract][Full Text] [Related]
5. Redistribution of imipramine from regions of the brain under the influence of circulating specific antibodies.
Ragusi C; Scherrmann JM; Harrison K; Smith DS; Rips R; Boschi G
J Neurochem; 1998 May; 70(5):2099-105. PubMed ID: 9572296
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of imipramine and its major metabolites in pregnant rats and their fetuses following a single dose.
DeVane CL; Simpkins JW
Drug Metab Dispos; 1985; 13(4):438-42. PubMed ID: 2863107
[TBL] [Abstract][Full Text] [Related]
7. Chronic dosage of imipramine in animal experiment: concentrations of imipramine and desipramine in the rat brain after various modes of dosage.
Melzacka M; Rurak A; Danek L; Daniel W; Vetulani J
Pol J Pharmacol Pharm; 1985; 37(4):525-32. PubMed ID: 4080646
[TBL] [Abstract][Full Text] [Related]
8. Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients.
Sutfin TA; Perini GI; Molnar G; Jusko WJ
J Clin Psychopharmacol; 1988 Feb; 8(1):48-53. PubMed ID: 3350999
[TBL] [Abstract][Full Text] [Related]
9. Effects of combined treatment with imipramine and metyrapone in the forced swimming test in rats. Behavioral and pharmacokinetic studies.
Rogóz Z; Skuza G; Wójcikowski J; Daniel WA
Pol J Pharmacol; 2003; 55(6):993-9. PubMed ID: 14730094
[TBL] [Abstract][Full Text] [Related]
10. Effects of specific antibody Fab fragments on desipramine pharmacokinetics in the rat in vivo and in the isolated, perfused liver.
Keyler DE; Le Couteur DG; Pond SM; St Peter JV; Pentel PR
J Pharmacol Exp Ther; 1995 Mar; 272(3):1117-23. PubMed ID: 7891324
[TBL] [Abstract][Full Text] [Related]
11. The effect of prolonged administration of imipramine on its hepatic metabolism in rats.
Daniel W; Melzacka M
Pol J Pharmacol Pharm; 1987; 39(2):135-41. PubMed ID: 3432159
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment with drug-specific antibody reduces desipramine cardiotoxicity in rats.
Pentel PR; Brunn GJ; Pond SM; Keyler DE
Life Sci; 1991; 48(7):675-83. PubMed ID: 1990238
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of imipramine after single and multiple intravenous administration in rats.
Szymura-Oleksiak J; Panas M; Chruściel W
Pol J Pharmacol Pharm; 1983; 35(2):151-7. PubMed ID: 6622297
[TBL] [Abstract][Full Text] [Related]
14. Appropriate dosing regimens for treating juvenile rats with desipramine for neuropharmacological and behavioral studies.
Kozisek ME; Deupree JD; Burke WJ; Bylund DB
J Neurosci Methods; 2007 Jun; 163(1):83-91. PubMed ID: 17400296
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic interaction between imipramine and antidepressant neuroleptics in rats.
Daniel W
Pol J Pharmacol Pharm; 1991; 43(3):197-206. PubMed ID: 1683700
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression.
Szymura-Oleksiak J; Wyska E; Wasieczko A
Psychopharmacology (Berl); 2001 Feb; 154(1):38-42. PubMed ID: 11292004
[TBL] [Abstract][Full Text] [Related]
17. Chronopharmacokinetics of imipramine and desipramine in rat forebrain and plasma after single and chronic treatment with imipramine.
Lemmer B; Holle L
Chronobiol Int; 1991; 8(3):176-85. PubMed ID: 1794155
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of antidepressant-like activity by joint administration of imipramine and magnesium in the forced swim test: Behavioral and pharmacokinetic studies in mice.
Poleszak E; Wlaź P; Szewczyk B; Kedzierska E; Wyska E; Librowski T; Szymura-Oleksiak J; Fidecka S; Pilc A; Nowak G
Pharmacol Biochem Behav; 2005 Jul; 81(3):524-9. PubMed ID: 15936065
[TBL] [Abstract][Full Text] [Related]
19. Drug-specific F(ab')2 fragment reduces desipramine cardiotoxicity in rats.
Brunn GJ; Keyler DE; Ross CA; Pond SM; Pentel PR
Int J Immunopharmacol; 1991; 13(7):841-51. PubMed ID: 1761350
[TBL] [Abstract][Full Text] [Related]
20. Reversal of desipramine toxicity in rats with polyclonal drug-specific antibody Fab fragments.
Pentel PR; Ross CA; Landon J; Sidki A; Shelver WL; Keyler DE
J Lab Clin Med; 1994 Mar; 123(3):387-93. PubMed ID: 8133150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
